ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9%

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9%
Mon, 27 May

ASTRAZENECA PHARMA has announced its results for the quarter ended March 2019. Here is a detailed performance review of the same:

ASTRAZENECA PHARMA Quarterly Financials

No. of Mths
Qtr. Ending
3
Mar-18*
3
Dec-18*
3
Mar-19*
QoQ ChangeYoY Change
Net SalesRs m1,5072,1521,903-11.6%26.3%
Other incomeRs m23356072.0%157.1%
TurnoverRs m1,5312,1871,963-10.2%28.3%
ExpensesRs m1,3551,7431,8395.5%35.8%
Gross profitRs m15340964-84.4%-58.3%
DepreciationRs m3638393.4%10.1%
InterestRs m0000.0%0.0%
Profit before taxRs m14140685-79.1%-39.7%
TaxRs m108115-14-111.7%-112.5%
Profit after taxRs m3229198-66.2%204.9%
Gross profit margin%10.119.03.3
Effective tax rate%77.128.3-15.9
Net profit margin%2.113.35.0
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster


Year-on-Year Performance:
  • The company's operating income during the quarter grew 26.3% on a year-on-year (YoY) basis. The expenses were up by 35.8% YoY during the same period.
  • The company's operating profit declined by 58.3% YoY during the quarter. Consequently, operating profit margins witnessed a decline and stood at 3.3% in 4QFY19 as against 10.1% in 4QFY18.
  • Depreciation charges increased by 10.1% and finance costs increased by 0.0% YoY, respectively.
  • Other income increased by 157.1% YoY during the quarter.
  • Net profit for the quarter increased by 204.9% YoY. Net profit margins during the quarter increased from 2.1% in 4QFY18 to 5.0% in 4QFY19.
Quarter-on-Quarter Performance:
  • The company's operating income during the quarter fell 11.6% on a quarter-on-quarter (QoQ) basis. The expenses were up by 5.5% QoQ during the same period.
  • The company's operating profit declined by 84.4% QoQ during the quarter. Consequently, operating profit margins witnessed a decline and stood at 3.3% in 4QFY19 as against 19.0% in 3QFY18.
  • Net profit for the quarter declined by 66.2% QoQ, while net profit margins declined from 13.3% in 3QFY18 to 5.0% in 4QFY19.

To see how ASTRAZENECA PHARMA has performed over the last eight quarters, please visit here.

ASTRAZENECA PHARMA Share Price Performance

Over the last one year, ASTRAZENECA PHARMA share price has moved up from Rs 1,194.6 to Rs 2,089.9, registering a Gain of Rs 895.4 or around 75.0%.

Meanwhile, the S&P BSE HEALTHCARE Index is trading at Rs 13,392.0 (down 0.0%). Over the last one year it has moved up from 13,044.2 to 13,392.0, a gain of 348 points (up 2.7%).

Overall, the S&P BSE SENSEX is up 14.3% over the year.

Current Valuations

At the current price of Rs 2,089.9, the price to earnings (P/E) ratio of ASTRAZENECA PHARMA stands at 96.0 times its trailing twelve months earnings, while its price to book value (P/BV) ratio stands at 21.2 times.

Equitymaster requests your view! Post a comment on "ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9%". Click here!

  

Related Views on News

WOCKHARDT Surges by 6%; BSE HEALTHCARE Index Up 1.3% (Market Updates)

Jun 5, 2020 | Updated on Jun 5, 2020

WOCKHARDT share price has surged by 6% and its current market price is Rs 260. The BSE HEALTHCARE is up by 1.3%. The top gainers in the BSE HEALTHCARE Index are WOCKHARDT (up 5.6%) and JUBILANT LIFE SCIENCES (up 6.7%). The top losers are IPCA LABS (down 0.7%) and PROCTER & GAMBLE HEALTH (down 1.4%).

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY20); Net Profit Down 2.5% (Quarterly Result Update)

May 20, 2020 | Updated on May 20, 2020

For the quarter ended March 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 96 m (down 2.5% YoY). Sales on the other hand came in at Rs 2 bn (up 2.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Mar 29, 2019 | Updated on Mar 29, 2019

Here's an analysis of the annual report of ASTRAZENECA PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ASTRAZENECA PHARMA. Also includes updates on the valuation of ASTRAZENECA PHARMA.

More Views on News

Most Popular

6 Charts Showing the State of Indian Financial Markets in 2020(Sector Info)

May 26, 2020

Six charts showing how Indian financial markets have performed in 2020 so far...

Why We Picked This Smallcap Stock for a Post Coronavirus World(Profit Hunter)

May 28, 2020

Covid-19 has made it a survival of the fittest race for many companies. The ones that can adapt will thrive in a post crisis world.

What the RBI's Rate Cut Means for Options Traders(Fast Profits Daily)

May 25, 2020

The RBI governor has cut the repo rate to 4%. What does this mean for options traders? Find out in this video.

Who Will Be Crowned the 'Multibagger Blue Chip' of the Decade?(Profit Hunter)

May 25, 2020

Will the mutlibagger blue chips of the past decade continue to rule the bourses?

More

India's #1 Trader
Reveals His Secrets

The Secret to Increasing Your Trading Profits Today
Get this Special Report, The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Jun 5, 2020 02:53 PM

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 8-QTR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS